Mettrum Health Corp. sponsorship of Current Oncology sheds light on the benefit of cannabis for cancer patients.

TORONTO, April 5, 2016 /CNW/ - Mettrum Health Corp. ("Mettrum" or the "Company") (TSXV:MT), a vertically integrated producer of cannabis products, is proud to be the exclusive sponsor of a special issue of Current Oncology that highlights the use of cannabis for cancer patients. The supplement is aimed at informing the oncological community in Canada about the role that medical cannabis and cannabinoids can play in cancer management. The special issue is guest edited by Dr. Mark Ware, Director of Clinical Research, Alan Edwards Pain Management Unit, McGill University Health Centre, and Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids (CCIC).

"Finding answers to the questions regarding cannabis and cancer will require a concerted effort by patients, scientists, clinicians and the industry," said Dr. Mark Ware. "We at CCIC are proud to have stimulated this discussion, and we urge all stakeholders to move forward with the needed research to address an issue that really is a matter of life and death."

The treatment of cancer and its symptoms has been recognized as one of the most critical advances in cannabinoid therapeutics. "This issue brings together the work of some of the leading minds around the world who have dedicated themselves and their laboratories to understanding the role of cannabis and cannabinoids in the pathophysiology and management of cancer.  This collection of papers takes us on a journey from bedside to bench and back, and provides a series of important signposts that will help to chart a path to better cancer care," said Dr. Ware. Print copies of this supplement will be sent to Current Oncology's 3,200 subscribers. It is also available online, for free, at www.mettrum.com/oncology.

With new regulatory changes in Canada and the world over, access to a variety of quality-controlled cannabis-based products and administration techniques is becoming a reality for patients. "Mettrum is honoured to be a part of this initiative, helping educate oncologists and cancer patients about the possible role and benefits of cannabinoids," said Michael Haines, CEO of Mettrum. "By arming Canadians – patients, doctors and all those affected by cancer – with valuable knowledge about the use of medical cannabis for cancer care, we're hoping to help find suitable treatments for an illness that is known to impact two out of every five Canadians."

As a licensed producer of medical marijuana, Mettrum is dedicated to helping Canadians manage various illnesses and symptoms with cannabinoid therapies. The partnership with Current Oncology is one of many steps the company is taking to help educate the medical community on the benefits and possible clinical uses of medical cannabis.  Other initiatives include the Mettrum Spectrum™, a trademarked system that helps physicians and their patients select the cannabis strain or strains that are most appropriate for their particular medical need, and the recently launched Mettrum Registry Research Program (MRRP), a Canadian SHIELD ethics review board approved study that will systematically gather data on up to 6,000 Canadian patients that have been prescribed medical cannabis.

About Mettrum Health Corp
Mettrum Health Corp. is a Tier-1 Industry Issuer listed on TSX Venture Exchange. Mettrum Ltd., a wholly owned subsidiary, is a Toronto-based company and licensed producer of medical cannabis under the Marihuana for Medical Purposes Regulations (Canada) issued pursuant to the Controlled Drugs and Substances Act (Canada) (MMPR). The Company is a leading producer and vendor of medical cannabis under the MMPR system and has three licensed production facilities totalling 85,000 square feet representing annual production capacity of approximately 12,000 kilograms.

About the Mettrum Spectrum™
The Mettrum Spectrum™ is designed to simplify the dialogue around medical cannabis by categorizing Mettrum strains according to THC and CBD levels, using a straightforward, colour-coded system. The adoption of the Mettrum Spectrum™, allows health care practitioners to recommend strains to their patients with confidence. 

About the Mettrum Registry Research Program (MRRP)
Mettrum Health Corp. launched the Mettrum Registry Research Program (MRRP) in early March 2016, to systematically gather data on up to six thousand Canadian patients who have been prescribed medical cannabis. The goal of this observational study is to provide information to prescribing physicians and the wider medical community to help determine if and how cannabis should be prescribed – focusing on which strains best suit a particular patient's needs. It also considers the impact of intercurrent illness or potential interactions with other medications. The study will run for one year, with results anticipated to be published by March 2017. 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the results of operations. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company and Mettrum disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this Press release.

SOURCE Mettrum Health Corp.

Joanne D'Souza, Argyle Public Relationships, 416-968-7311 x236, [email protected]